Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 308Carcinoma, Non-Small-Cell Lung 241Prostatic Neoplasms 198Neoplasms 191Lung Neoplasms 149Multiple Myeloma 144Neoplasm Metastasis 110Colorectal Neoplasms 105Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 81Pancreatic Neoplasms 77Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 70Carcinoma, Renal Cell 68Lymphoma, Non-Hodgkin 64Squamous Cell Carcinoma of Head and Neck 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 59Urinary Bladder Neoplasms 58Recurrence 56Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Glioblastoma 53Endometrial Neoplasms 52Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Sarcoma 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 46

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × PRETEXT I Hepatoblastoma × 90 days × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡